journal
MENU ▼
Read by QxMD icon Read
search

Translational Lung Cancer Research

journal
https://www.readbyqxmd.com/read/27827467/ki-67-expression-in-pulmonary-tumors-reply
#1
EDITORIAL
Mark Kriegsmann, Arne Warth
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27827466/what-is-better-reliable-mitosis-counting-or-ki67-mib1-staining
#2
EDITORIAL
Mark Kriegsmann, Arne Warth
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27827465/ki-67-expression-in-pulmonary-tumors
#3
EDITORIAL
Lucian R Chirieac
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27827463/tumor-cell-proliferation-proliferative-index-and-mitotic-count-in-lung-cancer
#4
EDITORIAL
Lucian R Chirieac
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826537/professor-rafael-rosell-curiosity-for-knowledge-and-passion-for-all-human-beings-keep-me-motivated
#5
Chao-Xiu Melanie He
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826536/pembrolizumab-as-first-line-treatment-for-non-small-cell-lung-cancer-a-game-changer
#6
EDITORIAL
Wolfram C M Dempke, Klaus Fenchel
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826535/usefulness-of-circulating-free-dna-for-monitoring-epidermal-growth-factor-receptor-mutations-in-advanced-non-small-cell-lung-cancer-patients-a-case-report
#7
Clara Mayo de Las Casas, Maria Gonzalez-Cao, Santiago Viteri Ramirez, Nuria Jordana Ariza, Ariadna Balada, Mónica Garzón, Cristina Teixidó, Niki Karachaliou, Daniela Morales-Espinosa, Miguel Ángel Molina-Vila, Rafael Rosell
Genomic analysis of circulating tumor DNA (ctDNA) released from cancer cells into the bloodstream has been proposed as a useful method to capture dynamic changes during the course of the disease. In particular, the ability to monitor epidermal growth factor receptor (EGFR) mutation status in cell-free circulating DNA (cfDNA) isolated from advanced non-small cell lung cancer (NSCLC) patients EGFR can help to the correct management of the disease and overcome the challenges associated with tumor heterogeneity and insufficient biopsied material to perform key molecular diagnosis...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826534/fusion-gene-and-splice-variant-analyses-in-liquid-biopsies-of-lung-cancer-patients
#8
REVIEW
Cristina Aguado, Ana Giménez-Capitán, Niki Karachaliou, Ana Pérez-Rosado, Santiago Viteri, Daniela Morales-Espinosa, Rafael Rosell
Obtaining a biopsy of solid tumors requires invasive procedures that strongly limit patient compliance. In contrast, a blood extraction is safe, can be performed at many time points during the course disease and encourages appropriate therapy modifications, potentially improving the patient's clinical outcome and quality of life. Fusion of the tyrosine kinase genes anaplastic lymphoma kinase (ALK), C-ROS oncogen 1 (ROS 1), rearranged during transfection (RET) and neurotrophic tyrosine kinase 1 (NTRK1) occur in 1-5% of lung adenocarcinomas and constitute therapeutic targets for tyrosine kinase inhibitors...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826533/liquid-biopsy-in-early-stage-lung-cancer
#9
REVIEW
Cristina Pérez-Ramírez, Marisa Cañadas-Garre, Ana I Robles, Miguel Ángel Molina, María José Faus-Dáder, Miguel Ángel Calleja-Hernández
Lung cancer is the leading cause of cancer-associated deaths worldwide. Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC). However, 30% to 80% of these patients will die within 5 yearS of diagnosis. Circulating cell-free DNA (cfDNA) harbors pathologic characteristics of the original tumor, such as gene mutations or epigenetic alterations. Analysis of cfDNA has revolutionized the clinical care of advanced lung cancer patients undergoing targeted therapies. However, the low concentration of cfDNA in the blood of early-stage NSCLC patients has hampered its use for management of early disease...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826532/kras-mutations-in-the-circulating-free-dna-cfdna-of-non-small-cell-lung-cancer-nsclc-patients
#10
REVIEW
Mónica Garzón, Sergi Villatoro, Cristina Teixidó, Clara Mayo, Alejandro Martínez, Maria de Los Llanos Gil, Santiago Viteri, Daniela Morales-Espinosa, Rafael Rosell
Circulating free DNA (cfDNA) is obtained from serum or plasma by non-invasive methods such as a simple blood draw, a technique known as "liquid biopsy". Genetic analyses of driver alterations in cfDNA have proved very effective to predict survival and treatment response of cancer patients according to tumoral cfDNA burden in blood. Non-small cell lung cancer (NSCLC) patients with higher concentration of tumoral cfDNA in blood have, on average, shorter progression-free survival (PFS) and overall survival (OS)...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826531/next-generation-sequencing-techniques-in-liquid-biopsy-focus-on-non-small-cell-lung-cancer-patients
#11
REVIEW
Umberto Malapelle, Pasquale Pisapia, Danilo Rocco, Riccardo Smeraglio, Maria di Spirito, Claudio Bellevicine, Giancarlo Troncone
The advent of genomic based personalized medicine has led to multiple advances in the molecular characterization of many tumor types, such as non-small cell lung cancer (NSCLC). NSCLC is diagnosed in most cases on small tissue samples that may be not always sufficient for EGFR mutational assessment to select patients for first and second generations' tyrosine kinase inhibitors (TKIs) therapy. In patients without tissue availability at presentation, the analysis of cell free DNA (cfDNA) derived from liquid biopsy samples, in particular from plasma, represent an established alternative to provide EGFR mutational testing for treatment decision making...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826530/methylation-analyses-in-liquid-biopsy
#12
REVIEW
Delphine Lissa, Ana I Robles
Lung cancer is the leading cause of cancer-related deaths worldwide. Recent implementation of low-dose computed tomography (LDCT) screening is predicted to lead to diagnosis of lung cancer at an earlier stage, with survival benefit. However, there is still a pressing need for biomarkers that will identify individuals eligible for screening, as well as improve the diagnostic accuracy of LDCT. In addition, biomarkers for prognostic stratification of patients with early stage disease, and those that can be used as surrogates to monitor tumor evolution, will greatly improve clinical management...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826529/exosomes-genetic-cargo-in-lung-cancer-a-truly-pandora-s-box
#13
REVIEW
Pablo Reclusa, Rafael Sirera, Antonio Araujo, Marco Giallombardo, Anna Valentino, Laure Sorber, Ignacio Gil Bazo, Patrick Pauwels, Christian Rolfo
Lung cancer is a highly lethal disease. Targeted therapies have been developed in last years, however survival rates are not improving due to the delay in the diagnosis, making biomarkers one of the most interesting fields of study in cancer. Liquid biopsy has raised as an alternative to tissue biopsy due to improvements in analytical techniques for circulating tumor cells (CTCs), cell free DNA and exosomes. Among all, exosomes have raised as one of the most promising tools to understand the tumor due to their stability in the blood and their similarity to the cells of origin...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826528/circulating-tumor-cells-versus-circulating-tumor-dna-in-lung-cancer-which-one-will-win
#14
REVIEW
Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps
Liquid biopsies appear to be a reliable alternative to conventional biopsies that can provide both precise molecular data useful for improving the clinical management of lung cancer patients as well as a less invasive way of monitoring tumor behavior. These advances are supported by important biotechnological developments in the fields of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Analysis of CTCs and ctDNA may be useful in treatment selection, for response monitoring, and in studying resistance mechanisms...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826527/liquid-biopsy-based-biomarkers-in-non-small-cell-lung-cancer-for-diagnosis-and-treatment-monitoring
#15
REVIEW
David Pérez-Callejo, Atocha Romero, Mariano Provencio, María Torrente
Advances in the knowledge of the biology of non-small cell lung cancer (NSCLC) have revealed molecular information used for systemic cancer therapy targeting metastatic disease, with an important impact on patients overall survival (OS) and quality of life. However, a biopsy of overt metastases is an invasive procedure limited to certain locations and not easily acceptable in the clinic. Moreover, a single biopsy cannot reflect the clonal heterogeneity of the tumor. The analysis of peripheral blood samples of cancer patients represents a new source of cancer-derived material, known as liquid biopsy, and its components can be obtained from almost all body fluids...
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27826526/liquid-biopsy-in-lung-cancer-present-and-future
#16
Miguel Ángel Molina-Vila
No abstract text is available yet for this article.
October 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27676363/genomic-alterations-in-small-cell-lung-cancer-and-their-clinical-relevance
#17
COMMENT
Gary Wildey, Afshin Dowlati
No abstract text is available yet for this article.
August 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27659489/commentary-on-tumor-heterogeneity
#18
EDITORIAL
Helmut H Popper
No abstract text is available yet for this article.
August 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27657908/rebuttal-from-dr-hofman-and-dr-ili%C3%A3
#19
EDITORIAL
Marius Ilié, Paul Hofman
No abstract text is available yet for this article.
August 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/27657667/rebuttal-from-dr-mino-kenudson
#20
EDITORIAL
Mari Mino-Kenudson
No abstract text is available yet for this article.
August 2016: Translational Lung Cancer Research
journal
journal
49936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"